お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
997774

抗肥満薬の世界市場

Anti-Obesity Drugs

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 73 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

抗肥満薬の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 73 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の抗肥満薬の市場規模は、分析期間(2020年~2027年)に19.4%のCAGRで成長する見通しで、2020年の15億米ドルから、2027年には51億米ドルに達すると予測されています。

当レポートは、世界の抗肥満薬市場について調査しており、市場シェア、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Eisai Co. Ltd. (Japan)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc
  • Novo Nordisk A/S (Denmark)
  • Rhythm Pharmaceuticals (US)
  • VIVUS Inc. (US)

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
    • 肥満と過体重の統計
    • 最近の市場活動
    • 肥満-序文
    • 抗肥満薬:アンメットニーズが高いことを特徴とする市場
    • 現在利用可能な抗肥満薬
    • 現在利用可能な短期および長期の各抗肥満薬
    • 肥満の各適応外薬
    • SaxendaによるAOM市場の牽引、新薬の登場による市場成長への弾み
    • Semaglutide:AOMパイプラインで最も高い可能性
    • 過去の薬の挫折
    • Belviqの前向きな見通し
    • Xenicalのリニューアル
    • Contrave(R)のリニューアル
    • 市場の見通しを悪くする患者、医師、支払者の不信感
    • 新薬開発-市場の制約はあるものの、高い注目度
    • フェーズIII臨床試験における抗肥満薬:2018年7月時点
    • フェーズII臨床試験における抗肥満薬:2018年7月時点
    • フェーズI臨床試験における抗肥満薬:2018年7月時点
    • 糖尿病製薬企業の抗肥満薬の分野への参入
    • 競合情勢
    • Novo Nordisk-市場をリードする企業
    • 米国-最大の肥満および抗肥満市場
    • 欧州-大きな可能性を秘めた市場
    • 新興諸国で増加する肥満症
  • 主要企業
    • F. Hoffmann-La Roche Ltd. (スイス)
    • GlaxoSmithKline Plc. (英国)
    • Eisai Co., Ltd. (日本)
    • Novo Nordisk A/S (デンマーク)
    • Rhythm Pharmaceuticals (米国)
    • VIVUS, Inc. (米国)
  • 動向と推進要因
    • 世界の肥満レベルの驚くべき上昇-主な成長要因
    • BMIの分類
    • 肥満に関連する慢性疾患の発生率の上昇による市場拡大の促進
    • 市場成長を促進する中産階級の人口増加
    • 小児肥満症-アンメットニーズ市場
    • 商業減量企業の市場への参入
    • 売り上げを伸ばすオンラインドラッグストア
    • 効果的な薬の開発への障壁
    • 規制の追加-参入障壁?
    • 高い医薬品開発コスト-大きな後退
    • 減量剤の代替品-市場の弱体化
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:25社
目次
Product Code: MCP-1722

Abstract:

Global Anti-Obesity Drugs Market to Reach $5.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Anti-Obesity Drugs estimated at US$1.5 Billion in the year 2020, is projected to reach a revised size of US$5.1 Billion by 2027, growing at a CAGR of 19.4% over the period 2020-2027.

The U.S. Market is Estimated at $443.3 Million, While China is Forecast to Grow at 19% CAGR

The Anti-Obesity Drugs market in the U.S. is estimated at US$443.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$903.4 Million by the year 2027 trailing a CAGR of 19% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.2% and 16.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

Select Competitors (Total 25 Featured) -

  • Eisai Co. Ltd. (Japan)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc
  • Novo Nordisk A/S (Denmark)
  • Rhythm Pharmaceuticals (US)
  • VIVUS Inc. (US)

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Obesity and Overweight Statistics
    • Recent Market Activity
    • Obesity - A Prelude
    • Anti-Obesity Drugs: A Market Characterized by High Unmet Needs
    • Currently Available Anti-Obesity Medications
    • Select Currently Available Short-term and Long-term Anti-Obesity Medication
    • Select Off-Label Drugs for Obesity
    • Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth
    • Semaglutide: Highest Potential in the AOM Pipeline
    • Setbacks of Past Drugs
    • Positive Road Ahead for Belviq
    • Relaunch of Xenical
    • Relaunch of Contrave®
    • Reluctance among Patients, Physicians, and Payers Hurts Market Prospects
    • New Drug Development - High on the Agenda, Despite the Market Restraints
    • Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018
    • Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018
    • Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018
    • Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space
    • Competitive Landscape
    • Novo Nordisk - The Leading Player in the Market
    • The United States - The Largest Obesity and Anti-Obesity Market
    • Europe - A Market with Vast Potential
    • Obesity Creeps Up in Developing Countries
  • 2. FOCUS ON SELECT PLAYERS
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • GlaxoSmithKline Plc. (UK)
    • Eisai Co., Ltd. (Japan)
    • Novo Nordisk A/S (Denmark)
    • Rhythm Pharmaceuticals (USA)
    • VIVUS, Inc. (USA)
  • 3. MARKET TRENDS & DRIVERS
    • Alarming Rise in Global Obesity Levels - The Major Growth Factor
    • Classification of BMI
    • Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion
    • Growing Middle Class Population to Drive the Market Growth
    • Childhood Obesity - A Market with Unmet Needs
    • Commercial Weight-Loss Companies Foray into the Market
    • Online Drug Stores Boost Sales
    • Barriers to Development of Effective Drugs
    • Regulatory Additions - A Barrier to Entry?
    • High Drug Development Costs - A Major Setback
    • Weight Loss Alternatives - A Market Dampener
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 3: USA Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • CANADA
    • TABLE 4: Canada Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • JAPAN
    • TABLE 5: Japan Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • CHINA
    • TABLE 6: China Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • EUROPE
    • TABLE 7: Europe Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: Europe 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • FRANCE
    • TABLE 9: France Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • GERMANY
    • TABLE 10: Germany Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • ITALY
    • TABLE 11: Italy Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • UNITED KINGDOM
    • TABLE 12: UK Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • REST OF EUROPE
    • TABLE 13: Rest of Europe Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • ASIA-PACIFIC
    • TABLE 14: Asia-Pacific Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • REST OF WORLD
    • TABLE 15: Rest of World Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

IV. COMPETITION

  • Total Companies Profiled: 25
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.